Bimi International Medical Inc. BIMI
We take great care to ensure that the data presented and summarized in this overview for BIMI International Medical Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BIMI
Top Purchases
Top Sells
About BIMI
BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes generic drugs, Chinese herbal medicine, biochemical drugs, raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, health foods, sundry products, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is based in Chongqing, the People's Republic of China.
Insider Transactions at BIMI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 12
2024
|
Fnu Oudom Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,123,500
+42.53%
|
-
|
Feb 28
2024
|
Song Tiewei CEO |
SELL
Open market or private sale
|
Direct |
4,000
-1.17%
|
$16,000
$4.08 P/Share
|
Feb 26
2024
|
Song Tiewei CEO |
SELL
Open market or private sale
|
Direct |
724
-0.21%
|
$2,896
$4.01 P/Share
|
Jul 19
2022
|
Fnu Oudom Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500,000
+50.0%
|
$0
$0.4 P/Share
|
Jul 19
2022
|
Song Tiewei CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+7.55%
|
$4,984,000,000
$49840.0 P/Share
|
Jul 18
2022
|
Song Tiewei CEO |
BUY
Grant, award, or other acquisition
|
Direct |
124,427
+9.96%
|
$7,318,422,859
$58817.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.12M shares |
---|
Open market or private sale | 4.72K shares |
---|